Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Profiling intranasal esketamine for adults with major depressive disorder and acute suicidal ideation or behavior: a phenotype-informed drug profile.

Expert review of neurotherapeutics - 1 Sept 2026

Pinzi Mario, Cuomo Alessandro, Rescalli Maria Beatrice, Pierini Caterina, Fagiolini Andrea

Abstract excerpt

INTRODUCTION: Acute suicidal ideation in major depressive disorder (MDD) is a psychiatric emergency requiring rapid risk assessment, containment, and treatment. Conventional monoaminergic antidepressants have delayed onset, leaving an interval during which severe depressive distress persists. Intranasal esketamine, a rapid-acting N-methyl-D-aspartate receptor antagonist, is approved for MDD with acute suicidal...

Read the complete abstract on PubMed

Topics

Humans
Major Depressive Disorder
Suicidal Ideation
Administration, Intranasal
Ketamine
Antidepressive Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Phenotype

Adult

Source

Identifiers

PMID: 42610482
DOI: 10.1080/14737175.2026.2714839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Profiling intranasal esketamine for adults with major depressive disorder and acute suicidal ideation or behavior: a phenotype-informed drug profile.PMID 42610482Read ↗

Real-world patient characteristics, treatment patterns, efficacy and safety of intramuscular ketamine treatment: a retrospective cohort studySemantic proximity Read ↗

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extensionSemantic proximity Read ↗

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Verify the Efficacy and Safety of Ansofaxine (LY03005) for Major Depressive DisorderSemantic proximity Read ↗

Ketamine in severe, highly treatment-resistant depression—a retrospective case study and a perspectiveSemantic proximity Read ↗

Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studiesSemantic proximity Read ↗

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets.Semantic proximity Read ↗

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.Semantic proximity Read ↗

[Personalized treatment of depression phenotypes: role of trazodone in depression with insomnia].Semantic proximity Read ↗

Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical OutcomesSemantic proximity Read ↗

Genome-wide association study and polygenic risk score analysis of esketamine treatment response.Semantic proximity Read ↗

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)Semantic proximity Read ↗

Propofol for treatment resistant depression: A randomized controlled trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.